Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 USD | -7.56% | -8.33% | +24.11% |
Jun. 04 | Top Premarket Gainers | MT |
Jun. 03 | FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier | MT |
Financials (USD)
Sales 2024 * | 150M | Sales 2025 * | 152M | Capitalization | 109M |
---|---|---|---|---|---|
Net income 2024 * | -154M | Net income 2025 * | -93M | EV / Sales 2024 * | 0.73 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.72 x |
P/E ratio 2024 * |
-0.71
x | P/E ratio 2025 * |
-1.18
x | Employees | 486 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.11% |
Latest transcript on FibroGen, Inc.
1 day | -7.56% | ||
1 week | -8.33% | ||
Current month | -8.33% | ||
1 month | -19.71% | ||
3 months | -38.55% | ||
6 months | +78.75% | ||
Current year | +24.11% |
Managers | Title | Age | Since |
---|---|---|---|
Thane Wettig
CEO | Chief Executive Officer | 59 | 20-06-21 |
Juan Graham
DFI | Director of Finance/CFO | 48 | 21-09-06 |
James Schoeneck
CHM | Chairman | 66 | 10-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Edwards
BRD | Director/Board Member | 63 | 15-10-27 |
Director/Board Member | 59 | 15-08-05 | |
May Kin Ho
BRD | Director/Board Member | 71 | 18-12-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.83% | 1 M€ | +0.84% | - | |
0.13% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 1.1 | -7.56% | 1,940,398 |
24-06-06 | 1.19 | -1.65% | 1,940,803 |
24-06-05 | 1.21 | +2.54% | 2,570,775 |
24-06-04 | 1.18 | -4.07% | 13,524,533 |
24-06-03 | 1.23 | +2.50% | 6,779,515 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.11% | 109M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- FGEN Stock